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receive vaccine via G1 or NS. Seroconversion rates against measles and mumps viruses in
the G1 treatment group did not meet non-inferiority criteria when compared with the NS
group; however, responses in the G1 group to rubella virus were non-inferior to those of NS
vaccinees. Most adverse events were mild or moderate. Crying after injection was more
frequent in the NS group, and local skin reactions were more common in the G1 group. Five
serious adverse events were judged causally unrelated to treatment and all resolved.
Parents/guardians expressed a strong preference for G1 over NS for their children.
Vaccinators found the G1 easy to use but noted incomplete vaccine delivery in some
cases. Although the G1 has been superseded by an updated device, our results are important
for the continued improvement and evaluation of DSJIs, which have the potential to
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42 This vaccine is currently used exclusively in the Brazil National Immuni-
zation Program.1. Introduction
Disposable-syringe jet injectors (DSJIs) are needle-free
devices that employ a sterile, single-use syringe to administer
vaccines with a fine stream of pressurized, high-velocity liquid
that penetrates the skin [1,2]. The liquid typically is propelled by
release of a piston powered by a compressed spring or gas. DSJIs
were developed to address risks associated with a type of device
used earlier, the multiple-use nozzle jet injector (MUNJI), after
evidence of cross-contamination between patients [1,3–5]. Prior
to this, MUNJIs had been widely used in mass immunization
campaigns [6,7] and in the military.
Several DSJIs have been approved and marketed in the
United States and Europe [1]. They are capable of delivering all
injectable vaccines used in immunization programs, whether
into intradermal, subcutaneous, or intramuscular tissues, and
have the potential to overcome many of the challenges and
risks associatedwith needle-based injections and sharpswaste.
DSJIs that are particularly attractive for use in developing-
country programs are low cost and use manually compressed
springs rather than compressed gas.
Antibody responses to vaccines administered by DSJIs
generally have been reported as comparable or superior to
those induced by needle and syringe (NS). Vaccines shown to
induce immunity when given by DSJI include typhoid,
diphtheria, pertussis, hepatitis A [8,9], influenza [10–13], and
measles–mumps–rubella (MMR) [14]. To date, no immunoge-
nicity data have been published forMMR vaccine administered
with the DSJI tested in this study.
The reported rates of local adverse events (AEs) (e.g., edema,
erythema, tenderness) have been higher for DSJI delivery than
for NS [15], but events are generallymild [8,16,17]. Some studies
have found the pain during jet injection to be equivalent to or
less than that associated with injection using a conventional NS
[15], although other studies reported higher levels of pain with
DSJIs [10,12].
For DSJI technology to be adopted globally, data demon-
strating immunogenicity and safety of vaccination are impor-
tant. Another consideration includes acceptability of DSJIs by
patients or their parents/guardians and by vaccinators. To
provide an initial clinical evidence base for the potential use of
DSJIs in immunization programs, we conducted a randomized,
controlled trial in which healthy Brazilian infants aged 12 to
18 months received MMR vaccine via either DSJI or NS. The
primary aim of the study was to determine if the immunoge-
nicity of the vaccine delivered via DSJI was non-inferior to that
administered by NS. The comparison was made for each
vaccine antigen separately. Secondary aims were to collect
safety data and to survey parents and vaccinators for their
perceptions of the specific DSJI evaluated. We also recordedinsights on operational aspects of this study that will be useful
in future clinical trials of DSJIs.
2. Methods
2.1. Vaccine
MMR vaccine from Bio-Manguinhos used in this study
was formulated according to procedures transferred by
GlaxoSmithKline to Bio-Manguinhos.2 Each reconstituted
0.5-mL dose contained the following:
• ≥1000 CCID50 of measles live attenuated virus (Schwarz
strain),
• ≥5000 CCID50 of mumps live attenuated virus (RIT 4385
strain, derived from the Jeryl Lynn strain),
• ≥1000 CCID50 of rubella live attenuated virus (Wistar RA 27/
3 strain).
2.2. Injection devices
The DSJI used for subcutaneous (SC) vaccination in this
study was the first-generation PharmaJet system (PharmaJet;
Golden, CO, USA) shown in Fig. 1 and referred to hereafter as
the G1. The system consisted of two injectors: a blue device
described by the manufacturer's instructions as suitable for
adults and children aged two years and older, and a purple
injector suitable for infants and for children up to two years old.
The G1 had the United States Food and Drug Administration
(FDA) (510(k) number K081532, 26 February 2009) and
Brazilian Health Surveillance Agency (Agência Nacional de
Vigilância Sanitária [ANVISA]) regulatory clearance at the time
of the study. The blue injector was used for two pilot studies
and the purple injector was used for the infant study reported
here. These injectors are spring-powered. Both G1 injectors
(blue and purple) were superseded by the PharmaJet Stratis
device in late 2011 and are no longer available.
The vaccine in the NS treatment group was administered
with sterile, single-use, disposable needles (13 × 4.5, Brazilian
scale; 26 gauge, 5/8 in., US scale) and 3-mL-capacity, sterile,
single-use, disposable syringes (BD).
2.3. Study populations and setting
The study was conducted at three public health immuniza-
tion clinics operated by the Health Secretary of Rio de Janeiro:
Guadalupe, Irajá, and Rocinha. Adult and pediatric pilot studies
Fig. 1. The first-generation PharmaJet system (G1) for vaccine delivery with
charging station, vial adapter, and syringe.
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assess immediate injection-site results. These studies included
ten healthy adult males aged 18 to 50 years and 15 healthy
children aged four to six years (data not shown). The study
reported here was conducted on healthy infants aged 12 to
18 months from August 2010 through March 2011.
Eligibility criteria required that participants be in good
health and not enrolled in another research study. They were
not to have received their first dose of MMR vaccine and were
required to be up to date on all other routine vaccines included
in Brazil's Basic Child Vaccination Schedule. They were not to
have received any other injectable vaccines within 28 days
prior to the study. Written informed consent was obtained
from all participants or parents/guardians. The study was
approved by the research ethics committee of the Municipal
Health Department of Rio de Janeiro, the Brazilian National
Research Ethics Commission (Comitê de Ética em Pesquisa
[CONEP]), and the PATH Research Ethics Committee, and was
registered as International Standard Randomized Controlled
Trial 4280032 [18].
The intention-to-treat (ITT) population included all en-
rolled infants who received an SC injection ofMMRvaccine and
had safety data recorded immediately and 60 min following
injection. All members of the ITT population were included in
safety and tolerability analyses.
The per-protocol (PP) population comprised those infants
in the ITT population (thus meeting all eligibility criteria listed
above) who received an SC injection of MMR vaccine and had a
post-vaccination blood sample taken within 35 to 56 days after
vaccination. A subject was included in the PP population for
analysis of any antibody for which he or she was negative at
baseline. For example, a subject who had not previously
received MMR and was baseline-positive for antibody against
the measles antigen (due to prior exposure) but negative for
the other two antibodies was excluded from the PP populationfor the analysis of measles antibody. However, that individual
was still a member of the PP population for the analysis of
mumps and rubella antibody responses.
2.4. Vaccinations and study visits
The treatment consisted of a 0.5-mL dose of MMR vaccine
administered SC in the left deltoid area, using either the G1 or
NS. Infants were randomized 2:1 to receive vaccine via G1 or
NS, respectively. This allocation ratio emphasizes the experi-
mental group, allowing better use of resources to generate
more data for the G1 [19]. There were three clinic visits. The
first visit included a baseline blood draw, vaccination, and
monitoring of AEs immediately and at 60 min following
vaccination. The second visit occurred within days 8 to 28
after the day of vaccination and included the collection of AEs
recorded in diaries, plus a review of delayed local and systemic
AEs. The third visit occurred within days 35 to 56 after the day
of vaccination and included the post-vaccination blood draw
and evaluation of delayed local or systemic AEs.
2.5. Immunogenicity assessment
Enzyme-linked immunosorbent assays (ELISAs) were per-
formed at theRespiratoryVirus Laboratory of InstitutoOswaldo
Cruz (Fiocruz, Rio de Janeiro). The plaque reduction neutrali-
zation test (PRNT) was performed at the Virologic Technology
Laboratory of Bio-Manguinhos (LATEV, Fiocruz, Rio de Janeiro).
The geometric mean concentration (GMC) for antibodies to
each antigen was also calculated for the two treatment groups.
Parents/guardians of infants in either study arm who failed
to seroconvert to any of the three vaccine antigens were
contacted after the study and offered an additional MMR dose
delivered by NS.
The immunogenicity of the MMR vaccine was assessed
primarily as a percentage of baseline-negative infants who
seroconverted for antibodies against each of the three vaccine
components—measles, mumps, and rubella viruses. Serocon-
version (SeroC) was calculated separately for each vaccine
antigen as the percentage of baseline-negative vaccinees having
a post-vaccination antibody level greater than or equal to the
following cutoff levels:
• Anti-measles neutralizing titer (NT):≥200milli-international
units per mL (mIU/mL) by PRNT (methods described in
reference [26]).
• Anti-mumps Immunoglobulin G (IgG): ≥231 units/mL by
ELISA, or if b231 units/mL by ELISA (Enzygnost® anti-
parotitis-virus/IgG, Siemens-Behring) and retested by PRNT,
then a positive test at a dilution ≥1:10.
• Anti-rubella IgG: ≥4 IU/mL by ELISA (Enzygnost® anti-
rubella-virus/IgG, Siemens-Behring).
Non-inferiority was defined a priori as a difference of less
than 10% on the upper limit of the 95% confidence interval (CI)
for the difference in SeroC rates between the two treatment
groups (SeroCNS–SeroCG1). The sample sizewas calculatedwith
Power Analysis & Sample Size Software (PASS) 2008 (Number
Cruncher Statistical Systems, Kaysville, Utah). Data were
analyzed using SPSS predictive analytics software, version
16.0 (SPSS, Inc., Chicago, Illinois). With an allocation ratio G1:
NS of 2:1, it was calculated that the sample should be 348 G1
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With these group sizes, if both true proportionswere 85%, then
the power to find the G1 statistically non-inferior to NS would
be 88%. To allow for 10% loss of data due to causes such as
subject withdrawal and some subjects having detectable pre-
vaccination titers, the targeted sample size was increased to a
total of 388 plus 194 to equal 582. We also calculated a 95% CI
for the ratio of the GMCs (separately for antibody to each of the
vaccine antigens) among subjects in the NS and G1 treatment
groups (GMCNS/GMCG1). If the upper limit of the 95% CI for the
ratio was b1.5, then the null hypothesis of inferiority of the G1
treatment group would be rejected.
For post hoc analyses on immunogenicity, a series of
univariate and multivariate regression analyses were done to
assess the importance of several independent variables (e.g., age
and gender of vaccinees, duration of injector use, or loss of
vaccine at the injection site) regarding SeroC rates or log10 of the
titer of antibodies against measles, mumps, and rubella viruses
as dependent variables. For analyses of incomplete delivery or
loss of vaccine, data were gathered from vaccinators' qualitative
observations of the injection as prompted by specific fields and
open-ended comment sections in the case report form (CRF).
2.6. Safety assessment
The safety and tolerability of vaccination was assessed in
terms of the following AEs: 1) local injection-site reactions and
systemic AEs observed immediately upon vaccination as well
as 60 min later by a clinic physician blinded to the method of
injection, 2) local injection-site reactions and systemic AEs
recorded by parents on a diary card for days 1 through 10 or
otherwise ascertained by study staff during the second clinic
visit, and 3) delayed local injection-site reactions and systemic
AEs ascertained by study staff during the third clinic visit. The
possible, probable, or definite relationship of AEs to treatment
(vaccine, injection device, or other aspect of treatment) was
determined by the principal investigator. Parents/guardians
and study staff were aware of the injection method. Pearson's
chi-square test or Fisher's exact test was used, as appropriate for
the comparison (Fisher's exact test was used when an observed
cell was b5), to evaluate the statistical significance of the
differences in AEs between the treatment groups, with p≤ 0.05
defined as significant. p-Values were not adjusted for multiple
comparisons and were calculated for reference purposes only.
Pre-specified local injection site signs and symptoms
included pain, laceration, bruising, induration, swelling, ery-
thema, warmth, and pus or drainage. Pre-specified systemic
AEs included anaphylaxis, swelling under the jaw line, rash,
irritability/crying, loss of appetite, sleepiness, and fever
(axillary temperature ≥37.5 °C).
2.7. Performance, acceptability, and usability of injection devices
Qualitative information regarding the use, performance,
and acceptability of the two methods of injection—by G1 or
conventional NS—was collected, with emphasis on the follow-
ing assessments: 1) the incomplete delivery of vaccine, which
could have implications for immune response; 2) the percep-
tions of the provider and parent/guardian of the subject
regarding use and acceptability; and 3) ease of use and
human factors. Injection performance and human factor datawere recorded by vaccinators in the CRF after each vaccination
to document delivery of the vaccine. Following each injection,
parents/guardians of infants were asked by the vaccinator to
rate qualitatively the injection experience (poor, acceptable, or
excellent) and indicate whether they would like to have their
child receive a future vaccination using the same mode of
injection. Monitoring of vaccinators during the study showed
that theywere employing the recommended techniques for G1
and NS injections.
3. Results
3.1. Study populations
The ITT population consisted of 582 healthy infants. There
were no significant differences between subjects in the two
treatment groups with respect to the ratio of males to females,
age, weight, height, or skin color. Median age was 13 months
(range 12.0–18.8; four subjects from 18.1 to 18.8 months of
age, all in the G1 group, were considered to meet eligibility
requirements); median weight was approximately 10 kg
(range 6.6–17.0). Of the 582 subjects, 573 had a blood sample
of sufficient volume for determination of antibodies against the
three viral antigens. However, 21 of these had the sample taken
outside the pre-specified window of days 35 to 56 and so were
not eligible for inclusion in the PP population for the analysis of
antibody responses by treatment group, leaving a PP popula-
tion of 552. In addition, five pre-vaccination blood samples
contained antibodies at a level above the designated cutoff
for antibodies against measles virus (≥200 mIU/mL); antibody
levels in samples from four individuals were above the
designated cutoff for antibodies against mumps virus
(≥231 units/mL); and one sample was too small to permit
necessary retesting for antibodies against mumps virus. Thus,
547 infants met the criteria for inclusion in the PP population
for analysis of antibodies against measles and mumps viruses;
for rubella the PP population was 552.
3.2. Immunogenicity assessment
Table 1 shows by treatment group the SeroC rates for
antibodies to measles, mumps, and rubella viruses among
baseline-negative infants in the PP population 35 to 56 days
after receiving an injection of MMR vaccine. For antibodies to
rubella virus, the upper limit of the 95% CI for the difference
SeroCNS–SeroCG1 was b10%, meeting the criterion for non-
inferiority. For antibodies against measles and mumps viruses,
the upper limits of the 95% CIwere N10%; thus, the responses in
the G1 treatment group did not meet non-inferiority criteria.
GMCs of serum antibodies against the three vaccine
components also were estimated. For antibodies to both
measles and mumps viruses, the upper limit of the 95% CIs for
the ratio GMCNS/GMCG1 for subjects in the PP population
exceeded the protocol-defined limit of 1.5, while for antibodies
against rubella virus it was less than 1.5 (Table 1). Thus, the
GMCs for measles and mumps vaccine components delivered
by the G1 did not meet the non-inferiority definition for
comparison with NS, but those for rubella virus were non-
inferior, mirroring the results of the SeroC rates. Families of all
infantswhodid notmount an adequate responsewere notified,
and all of these infants subsequently were re-vaccinated.
Table 1
Seroconversion (SeroC) rates and geometric mean concentrations for antibodies against measles, mumps, and rubella viruses by treatment group among baseline-
negative subjects following an injection of measles–mumps–rubella vaccine (per-protocol [PP] population).
Antibody Treatment group
(Total N subjectsa)
Subjects sero-converting
N (%)
SeroCNS–SeroCG1
(95% CI)
Geometric mean concentration
(GMC)
GMCNS/GMCG1
(95% CI)
Anti-measles NT NS (182) 182 (100.0) 9.3 (5.9, 12.7) 4996.75 mIU/mL 1.40 (1.19, 1.64)
G1 (365) 331 (90.7) 3563.20 mIU/mL
Anti-mumps IgGb NS (183) 140 (76.5) 14.4 (6.1, 22.7) 661.20 U/mL 1.57 (1.27, 1.92)
G1 (364) 226 (62.1) 422.27 U/mL
Anti-rubella IgG NS (184) 183 (99.5) 0.3 (−1.5, 2.1) 43.05 IU/mL 1.01 (0.87, 1.18)
G1 (368) 365 (99.2) 42.47 IU/mL
a The number of subjects for the anti-rubella PP populationwas 552. Because four subjects had high pre-vaccination antibody blood levels and one had an inadequate
blood sample, the number for anti-measles and anti-mumps PP populations was 547.
b Includes two subjects in the G1 group negative by ELISA but positive by PRNT retest.
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against measles and mumps viruses among subjects in the G1
treatment group did not meet non-inferiority criteria com-
pared with those of infants in the NS treatment group, we
conducted a number of post hoc analyses to identify factors
that may have contributed to the diminished antibody
responses in the G1 treatment group. Several variables were
found to have a significant effect on SeroC rates among subjects
in the G1 treatment group for antibodies against measles and/
or mumps virus but not for antibodies against rubella virus.
In the G1 group, female gender (p = 0.032, Pearson's chi-
square) and children 12 to b13 months (p = 0.016, Pearson's
chi-square),were associatedwith a lower SeroC rate formeasles
antibody, and in univariate regression analysis female gender
was marginally associated with a lower SeroC rate for mumps
antibody (odds ratio [OR] 0.656, p= 0.052). Lower bodyweightTable 2
Number of subjects with local and systemic adverse events (AEs) observed in at least 4
following an injection of measles–mumps–rubella vaccine (intention-to-treat [ITT] po
Time of observation Type of AE NS
Immediately Injection-site AE
• Blood at injection site
• Papules
Systemic AE
• Short cry 15
• Inconsolable cry 2
Total with immediate AEsa
60 min Injection-site AE
• Erythema 1
Systemic AE
• Sleepiness
Total with AEs at 60 mina
Days 1 10 Injection-site AE
• Pain 2
• Erythema 1
• Swelling 1
Systemic AE
• Fever
Any (≥37.5 °C) 85
High fever (≥39 °C) 22
• Loss of appetite 8
• Sleepiness 3
• Irritability 4
• Rash 1
Total with AEs in days 1 10a
a Numbers in “Total” rows refer to the total number of subjects with adverse events,
those AEs reported in ≥4% of subjects.
b Note that denominators are lower in some cases. This is because a smaller numbe
c Pearson's chi-square test or Fisher's exact test was used, as appropriate for the comalso exhibited a lower, but not statistically significant, SeroC rate
for measles antibody (OR 0.498, p = 0.063).
In a further multivariable regression analysis, we looked for
evidence of possible incomplete delivery of vaccine, noted by
vaccinators on the CRF as “failure to inject 0.5 mL,”“liquid or
vaccine at the injection site,” or “spray at injection.” These
observations were reported for 13% of vaccinations in the NS
treatment group and 58% in the G1 treatment group. Incom-
plete deliverywas significantly associatedwith a reduced SeroC
rate formumps antibody (p= 0.044) and lowermeasles GMCs
in the G1 treatment group (p = 0.047).
3.3. Safety assessment
Vaccination was generally well tolerated by infants in both
treatment groups, but there were statistically significant% of vaccinees in either treatment group immediately, 60 min, and 1 to 10 days
pulation).
G1 p-Valuec
9/194 (4.6%) 8/388 (2.1%) 0.082
1/194 (0.5%) 36/388 (9.3%) b0.001
3/194 (78.9%) 152/388 (39.2%) b0.001
1/194 (10.8%) 6/388 (1.5%) b0.001
174 (89.7%) 183 (47.2%) b0.001
0/194 (5.2%) 92/388 (23.7%) b0.001
9/194 (4.6%) 17/388 (4.4%) 0.877
24 (12.4%) 112 (28.9%) b0.001
5/193 (13.0%) 33/384 (8.6%) 0.100
6/192 (8.3%) 80/384 (20.6%) b0.001
7/192 (8.9%) 80/383 (20.9%) b0.001
/153b (55.6%) 109/277 (39.4%) 0.001
/153b (14.4%) 23/277 (8.3%) 0.049
1/193 (42.0%) 153/384 (39.8%) 0.624
7/193 (19.2%) 75/384 (19.5%) 0.918
1/193 (21.2%) 72/384 (18.8%) 0.476
2/193 (6.2%) 24/384 (6.3%) 0.988
137 (80.6%) 264 (78.8%) 0.640
and some subjects experiencedmore than one AE; in this tablewe included only
r of parents/guardians recorded this information.
parison.
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frequencies of pre-specified and other local and systemic AEs
noted immediately, at 60 min, and 1 to 10 days after injection.
Overall, the percentage of subjects with any AE immediately
following vaccination was significantly greater among subjects
in the NS treatment group compared with the G1 treatment
group (89.7% versus 47.2%, p b 0.001). Local AEs (mainly
papules) were more frequent among G1 vaccinees, while
crying following injection was more frequent in the NS
treatment group.
By 60 min, the proportion of subjects in the NS and G1
treatment groups with an AE declined to 12.4% and 28.9%,
respectively (Table 2). The difference between groups after 1 h
was largely due to the higher rate of local AEs (mostly
erythema at the injection site) in the G1 treatment group.
During days 1 through 10 (Table 2), the proportions of
subjects with one or more pre-specified AEs were similar in
both treatment groups (78.8% in the G1 group; 80.6% in the NS
group). G1 vaccinees continued to experience more local AEs
(mostly erythema and swelling at the injection site), while NS
vaccinees had slightly more systemic AEs, such as fever. No AE
reported during this timewas rated as serious. One NS vaccinee
had a local AE rated as severe (Grade 3 pain), while a small
proportion of subjects in both treatment groups (9.0% G1 to
13.5% NS) experienced at least one severe systemic AE. All
other local and systemic AEs were graded as mild or moderate
(Grade 1 or 2).
By the second clinic visit, the overall frequency of any
delayed AEs was 13.5% for the G1 group, compared with 15.0%
for the NS group, and by the third clinic visit, the frequency
declined to 6.5% compared with 4.2%, respectively. In addition
to these AEs, persistent injection site stigmata (e.g., scars,
hypochromia, macula, and papules) were noted as minor
events more prevalent among G1 comparedwith NS treatment
group subjects at both the second clinic visit (9.9% G1 versus
0.5% NS, p b 0.001, Fisher's exact test) and third clinic visit
(3.5% G1 versus 0.0% NS, p = 0.006, Fisher's exact test).
Five subjects in the study experienced a serious AE but all
events resolved and none were judged to have been related to
treatment. In the G1 treatment group, two were cases of
pneumonia and one was thought to be dengue. In the NS
treatment group, there was one case of a subgaleal hematoma
and one of meningitis. Among nine other significant AEs
(including five cases of pneumonia), two cases of pneumonia
with onset ten days after G1 vaccination were described as
possibly related and probably related to treatment; the other
events were judged not related.
3.4. Acceptability assessment
In the G1 treatment group 90.2%, 9.5%, and 0.3% of parents/
guardians rated the injection experience as excellent, accept-
able, and poor, respectively. The ratings forNSwere 7.2%, 62.9%,
and 29.9% for these descriptors. When asked about future
injections, 96.1% of families of infants vaccinated with the G1
indicated they would prefer it when their child needed an
injection, and 92.3% of families of infants injected with NS
indicated they would prefer an alternate mode of injection.
At each of the three study sites, one primary vaccinator
administered most of the injections. Filling the needle-free
syringe from the vaccine vial using the vial adapter was ratedby the vaccinators as easy for 99% of the injections. In
approximately 4% of cases, the vaccinator had to obtain another
syringe package or reattach/realign the syringe to the device.
The G1 was rated as easy to use for 99% of injections, and less
than 5%of the injectionswere noted as causing slight hand/arm
strain for the vaccinator. There were no reports of any
vaccinator injury related to the G1.
4. Discussion
Our study compared the immunogenicity of a MMR vaccine
administered via the G1 with that of the vaccine administered
via NS. While the results showed non-inferiority of SeroC rates
for G1 delivery of the rubella component of the vaccine, SeroC
and GMCs for the measles and mumps components did not
meet non-inferiority criteria. Our post hoc analyses showed
that some characteristics such as female gender and younger
age (12 to b13 months) were associated with a lower SeroC
rate for measles antibody, although the mechanisms by which
female gender or infant age might lead to lower SeroC are not
known. Incomplete delivery of vaccine was associated with
lower SeroC rates for mumps and lower measles GMCs. A small
amount of liquid on the surface of the skin is common following
DSJI injections; however, the high rate of incomplete injections
observed in our study and the relationship with lower immune
responses suggests that the G1 was not optimized for this age
group. Incomplete delivery was observed visually as wetness
on the skin, a spray in the air at the time of injection, or reflux of
vaccine from the puncture site. Visual observation is a
subjective method; use of a quantitative method formeasuring
liquid not injected might have strengthened the correlation
between volume of vaccine delivered and immune responses.
In the NS group, the performance of themeasles and rubella
vaccine components was excellent, and the SeroC and GMCs
were comparable to previous reports [20–24]. In contrast,
mumps immunogenicity by NS was poor, although the results
of this study are consistent with the immunogenicity variation
observed in several studies using the same MMR vaccines and
laboratorymethods [20–26]. The reasons for these variations in
immunogenicity have not yet been explained. It should be
noted that in one of these studies [27], vaccines from two
different MMR producers were used, and both had similar
mumps SeroC rates of around 70%.
The PharmaJet G1 used in this study has been superseded
by the PharmaJet Stratis and is no longer available. The Stratis
was designed to improve injection quality by reducing
incomplete injections and simplifying operation, helping to
reduce training requirements. The Stratis and another DSJI, the
Lectrajet® from D'Antonio Consultants International, Inc., have
recently been evaluated for delivery of trivalent inactivated
influenza vaccine, and results showed that vaccination with
DSJIs in these studies produced immune responses non-inferior
to those fromvaccinationwithNS [11,13]. Bench testing of both
the G1 and Stratis to assess whether jet injection affects the
viability of the live measles, mumps, and rubella viruses in the
vaccine found minimal loss of vaccine potency (written
communication, April 25, 2014: Melissa Coughlin, Marcus
Collins, and Paul Rota, all of United States Centers for Disease
Control and Prevention). Studies of MMR vaccine delivery to
infants with the Stratis device are needed to assess non-
inferiority to NS for this vaccine.
7R. de Menezes Martins et al. / Contemporary Clinical Trials 41 (2015) 1–8Vaccinationwas generally safe andwell tolerated by infants
who were administered MMR vaccine using either the G1 or
NS; G1 vaccinees hadmoreminor local injection-site AEs while
NS vaccinees had more crying, irritability, and fever. Vaccina-
tors found theG1 very easy to load anduse but noted a problem
with incomplete delivery of vaccine in a significant proportion
of vaccinees. Parents/guardians expressed a strong preference
for the G1 over NS as a mode of injection for their children,
whichmay be related to the significantly lower degree of crying
observed during and after injection with the G1.
Although the G1 system has been discontinued, our study
demonstrates the importance of evaluating new DSJIs and
provides insights for future studies. We suggest including the
following activities for any trial evaluating immunizations via
DSJIs:
• Include anNS control group receiving the same vaccine at the
same dose and depth of delivery as the DSJI group.
• Work closely with the DSJI manufacturer to train vaccinators
on the use of the device and to monitor the performance of
the devices used.
• Include quantitative measurement of loss of vaccine during
immunization. Methods for quantifying the volume of liquid
on the exterior of the skin and the device have beendeveloped
and used in other clinical studies, including weight-based and
absorption-based procedures [27,28], but qualitative observa-
tion is the only known method for reporting vaccine sprayed
in the air.
• Conduct interim analyses of injection performance to identify
and correct any device malfunctions or additional training
needs as they occur.
• Create a plan for re-immunization of subjects in any study
arm who do not exhibit an adequate immune response.
5. Conclusions
The DSJI is a promising technology with potential for use in
mass immunization campaigns and for routine immunization
programs in low- and middle-income countries. The use of a
sterile, single-dose, disposable, non-reusable syringe in these
devices eliminates the risk of blood-borne infections that can
be associated with the use of a needle and syringe, and the use
of a spring to power the injection makes the DSJI attractive for
settings that lack access to other power sources. Parents found
the G1 highly acceptable and vaccinators considered it easy to
use. While the specific DSJI used in this study cannot be
endorsed for use in immunization programs, and has been
discontinued, our experiences and recommendations may
inform future evaluations of newer DSJIs for routine infant
immunizations.
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